Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q3 FY22 results · Oct–Dec 2021
Neuland Laboratories reported revenue from operations of ₹236.47 crore (down 3.6% from Q3 FY21) and net profit of ₹12.94 crore (down 51.6% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 236.47 | 245.39 | −3.6% | 257.85 | −8.3% |
| Other income | 1.90 | 0.20 | +872.9% | 0.29 | +563.2% |
| Total income | 238.37 | 245.59 | −2.9% | 258.13 | −7.7% |
| Profit before tax | 18.24 | 31.95 | −42.9% | 27.58 | −33.9% |
| Net profit for the period | 12.94 | 26.74 | −51.6% | 20.37 | −36.5% |
| EPS, basic (₹) | 10.08 | 20.84 | −51.6% | 15.88 | −36.5% |
| Net margin (%) | 5.5 | 10.9 | 7.9 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 236.47 | 245.39 | −3.6% | 257.85 | −8.3% |
| Other income | 1.90 | 0.20 | +872.9% | 0.29 | +563.2% |
| Total income | 238.37 | 245.59 | −2.9% | 258.13 | −7.7% |
| Profit before tax | 18.10 | 31.86 | −43.2% | 27.53 | −34.3% |
| Net profit for the period | 12.73 | 26.67 | −52.3% | 20.33 | −37.4% |
| EPS, basic (₹) | 9.92 | 20.79 | −52.3% | 15.84 | −37.3% |
| Net margin (%) | 5.4 | 10.9 | 7.9 |
Consolidated
- Filed with BSE
- 01 Feb 2022, 16:10 IST
- Board meeting
- 01 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2022, 16:10 IST
- Board meeting
- 01 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE